Antibody-Based Biologics and Their Promise to Combat Staphylococcus aureus Infections. - Wikidata - wikimedia - TriplyDB

Antibody-Based Biologics and Their Promise to Combat Staphylococcus aureus Infections.

Antibody-Based Biologics and Their Promise to Combat Staphylococcus aureus Infections.

http://www.wikidata.org/entity/Q36609408

about

S. aureus blocks efferocytosis of neutrophils by macrophages through the activity of its virulence factor alpha toxin.Improved Protection in a Rabbit Model of Community-Associated Methicillin-Resistant Staphylococcus aureus Necrotizing Pneumonia upon Neutralization of Leukocidins in Addition to Alpha-Hemolysin.Differential epitope recognition in the immunodominant staphylococcal antigen A of Staphylococcus aureus by mouse versus human IgG antibodies.Multimechanistic Monoclonal Antibodies (MAbs) Targeting Staphylococcus aureus Alpha-Toxin and Clumping Factor A: Activity and Efficacy Comparisons of a MAb Combination and an Engineered Bispecific Antibody Approach.Leukocidins: staphylococcal bi-component pore-forming toxins find their receptors.Use of broadly neutralizing antibodies for HIV-1 prevention.Pharmacological Targeting of the Host-Pathogen Interaction: Alternatives to Classical Antibiotics to Combat Drug-Resistant Superbugs.Commercial Intravenous Immunoglobulin (IVIg) Preparations Contain Functional Neutralizing Antibodies Against the Staphylococcus aureus Leukocidin LukAB (LukGH).A human monoclonal antibody that specifically binds and inhibits the staphylococcal complement inhibitor protein SCIN.Safety and immunogenicity of a recombinant Staphylococcus aureus α-toxoid and a recombinant Panton-Valentine leukocidin subunit, in healthy adults.Staphylococcus aureus strain Newman D2C contains mutations in major regulatory pathways that cripple its pathogenesis.Prevalence of IgG and Neutralizing Antibodies Against Staphylococcus aureus Alpha Toxin in Healthy Human Subjects and Diverse Patient Populations.A natural human monoclonal antibody targeting Staphylococcus Protein A protects against Staphylococcus aureus bacteremia.Human antibody responses against non-covalently cell wall-bound Staphylococcus aureus proteins.A Novel Antimicrobial Coating Represses Biofilm and Virulence-Related Genes in Methicillin-Resistant Staphylococcus aureus.Antibody-Based Agents in the Management of Antibiotic-Resistant Staphylococcus aureus Diseases.Disarming Staphylococcus aureus from destroying human cells by simultaneously neutralizing six cytotoxins with two human monoclonal antibodies.Immunomodulation to Prevent or Treat Neonatal Sepsis: Past, Present, and Future Scientific real-time research problem-solving and pharmaceutical innovation

P2860

Q30822546-7E874F5B-478E-4BD3-8A03-9760D528DD11 Q37287867-2A5DCDA6-2622-46AB-9C4D-12F3A5922F4E Q38642002-7EF2DDC4-0E1C-4386-A45D-02A4234639CE Q38674449-7224E394-42F1-435D-8B09-AC4B3F3BE274 Q38728618-28AEE2C1-A3EF-497F-B007-6BFDCA9CF48A Q38764543-B5F52EB4-58D4-4739-8AA5-F546C78CF1BF Q39173330-FF2ABF26-4219-4FF2-8AB6-10DBDCF2C7BE Q40065980-DFFFAD0B-D9E7-4688-9611-9C8D96CE61CF Q40301010-EC908081-28C1-4711-8670-63815542B0FC Q40397499-87A5F72A-9C8E-4A71-9FC2-5416B9B50751 Q41996714-4809333E-10EB-4A38-A185-268B6C75ADE1 Q47273879-6EFD4E08-B0C8-4C99-A543-F26E406D7774 Q48174220-1C59215A-D2DC-4C21-9BE9-2C703DFD0C8C Q49830644-28914DA9-A94A-42D6-9A22-38D1EE0AC221 Q50351209-29801F19-E5A5-4E73-8926-B3F0E03DAE35 Q53702468-D4AAFB3C-7FB0-40DC-9C4E-EEDBAD530777 Q55074495-5302ABA8-0400-49B9-B14A-44ADA15D8D7B Q57175340-E7633BF7-8634-4789-AC18-9DD3DC429250 Q58252514-FFA672A7-D735-4B02-A04F-CB2308E4EBF8

P2860

Antibody-Based Biologics and Their Promise to Combat Staphylococcus aureus Infections.

http://www.wikidata.org/entity/Q36609408

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Antibody-Based Biologics and Their Promise to Combat Staphylococcus aureus Infections.

@ast

Antibody-Based Biologics and Their Promise to Combat Staphylococcus aureus Infections.

@en

type

label

Antibody-Based Biologics and Their Promise to Combat Staphylococcus aureus Infections.

@ast

Antibody-Based Biologics and Their Promise to Combat Staphylococcus aureus Infections.

@en

prefLabel

Antibody-Based Biologics and Their Promise to Combat Staphylococcus aureus Infections.

@ast

Antibody-Based Biologics and Their Promise to Combat Staphylococcus aureus Infections.

@en

P1433

Q36609408-C932BAC5-E90E-4610-A066-B2437291A65F

P1476

Q36609408-735ACFAC-5CDB-4F2E-9EAE-DA4A6FD13336

P2093

Q36609408-42FCA342-852E-4296-BD5B-058F53412DDC

Q36609408-AEF268C3-951B-4D18-9BFC-59DE01B92DC0

Q36609408-DF456741-53C8-4854-82CE-6DB07E2508DD

Q36609408-FF0840A4-563F-4615-92E1-2ABEDA4EC8D3

P2860

Q36609408-00AFA7A2-7D73-4217-BD06-BDC823DEB949

Q36609408-00EDDD66-30A6-4866-AA6D-D6D85C3865EB

Q36609408-035B366C-C97D-4755-81C0-F393A7F00067

Q36609408-045C0BB9-87B0-4801-885C-55491CA71DAD

Q36609408-04A48B08-20B3-4471-ADD3-25095C6AE95E

Q36609408-091D913D-7C37-490C-A5C2-090A434D3D18

Q36609408-0B15BB3B-C79F-45E8-B24A-6F6E8EAC39E4

Q36609408-0B8D22F6-0BA1-4ECD-8F65-38AEAFE7E774

Q36609408-0C0C28E0-CD5B-49C8-8E18-02614EEE7BEA

Q36609408-0DA3FF9E-AFB7-40F9-86BB-7A70643782C1

P304

Q36609408-F468AAB5-09FE-4152-BE64-907AF6DB5D46

P31

Q36609408-E2476739-A6E4-43DF-BE2F-A196FF30362A

P356

Q36609408-04DFD767-8833-4E33-B2C7-ECC69F537B50

P433

Q36609408-5247F0B1-6A90-45BE-B80C-D67E6415AE70

P478

Q36609408-8305E3B2-FEBC-4B6E-A25D-590D6C3623A8

P50

Q36609408-1BA27CE1-84C9-4DB8-8065-168C6181F726

P577

Q36609408-93BFD18E-1CFF-41E7-A3B3-A522C856ADED

P698

Q36609408-6D1E0BCD-06C6-4539-B4E5-04F7033BF001

P932

Q36609408-D5C315E3-483F-43E0-B07D-930CB2C5214D

P356

J.TIPS.2015.11.008

P1433

Trends in Pharmacological Sciences

P1476

Antibody-Based Biologics and Their Promise to Combat Staphylococcus aureus Infections.

@en

P2093

A Simon Lynch

http://www.w3.org/2001/XMLSchema#string

Peter T Buckley

http://www.w3.org/2001/XMLSchema#string

William E Sause

http://www.w3.org/2001/XMLSchema#string

William R Strohl

http://www.w3.org/2001/XMLSchema#string

P2860

Vaccine protection against Staphylococcus aureus pneumonia

Phase 1/2 double-blind, placebo-controlled, dose escalation, safety, and pharmacokinetic study of pagibaximab (BSYX-A110), an antistaphylococcal monoclonal antibody for the prevention of staphylococcal bloodstream infections, in very-low-birth-weigh

Staphylococcal manipulation of host immune responses

Staphylococcus aureus α-toxin: nearly a century of intrigue

Where does a Staphylococcus aureus vaccine stand?

Progress toward a Staphylococcus aureus vaccine

Staphylococcal superantigens in colonization and disease

Covering all the Bases: Preclinical Development of an Effective Staphylococcus aureus Vaccine

Staphylococcal alpha-phenol soluble modulins contribute to neutrophil lysis after phagocytosis.

Design of novel FN3 domains with high stability by a consensus sequence approach

P304

231-241

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.TIPS.2015.11.008

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

37

http://www.w3.org/2001/XMLSchema#string

P50

Victor J Torres

P577

2015-12-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26719219

http://www.w3.org/2001/XMLSchema#string

P932

4764385

http://www.w3.org/2001/XMLSchema#string